Pub Date : 2024-01-01DOI: 10.5114/pedm.2024.140935
Maciej Hilczer, Mieczysław Walczak
{"title":"Human growth hormone therapy - in three stages: past, present, and future.","authors":"Maciej Hilczer, Mieczysław Walczak","doi":"10.5114/pedm.2024.140935","DOIUrl":"10.5114/pedm.2024.140935","url":null,"abstract":"","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"30 2","pages":"49-50"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.5114/pedm.2024.140998
Dorota Roztoczyńska, Adrianna Kot-Marchewczyk, Anna Wędrychowicz, Artur Dobosz, Jerzy Starzyk
Introduction: The aim of the study is to analyze patients who do not respond adequately to human recombinant growth hormone (rhGH) treatment.
Material and methods: Four boys were analyzed: three patients diagnosed with SNP at the ages of 1) 8 years and 2 months, 2) 13 years and 2 months, 3) 16 years and 6 months, and patient 4) at the age of 6 years and 11 months - born small for gestational age (SGA). They underwent rhGH treatment.
Results: The expected growth improvement was not observed in all boys. Patient 1 was diagnosed with aortic coarctation, and after each attempt to increase the rhGH dose, nocturnal vomiting occurred - epilepsy was diagnosed. Patient 2 had severe foot pain. Patient 3 had delayed puberty - hypogonadotropic hypogonadism was diagnosed. Patient 4 had dysmorphic features. Genetic tests revealed the following: 1) mixed gonadal dysgenesis - modifying treatment; 2) Fabry disease - enzyme treatment and rhGH improved growth; 3) Kallmann syndrome - discontinuing rhGH for testosterone supplementation; 4) KBG syndrome.
Conclusions: 1. The presence of dysmorphic features and symptoms atypical for growth hormone deficiencies could warrant genetic diagnostics before initiating treatment. 2. Lack of significant improvement in growth is an indication for reevaluation of patients who have not completed growth. 3. Genetic studies in this patient group often elucidate the causes of slow growth rate. 4. The case authors have developed a proposal for a multicentre program aimed at establishing indications for genetic diagnosis in children diagnosed with SNP and SGA treated with rhGH.
{"title":"Indications for genetic diagnosis in children with growth hormone deficiency and born small for gestational age.","authors":"Dorota Roztoczyńska, Adrianna Kot-Marchewczyk, Anna Wędrychowicz, Artur Dobosz, Jerzy Starzyk","doi":"10.5114/pedm.2024.140998","DOIUrl":"10.5114/pedm.2024.140998","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study is to analyze patients who do not respond adequately to human recombinant growth hormone (rhGH) treatment.</p><p><strong>Material and methods: </strong>Four boys were analyzed: three patients diagnosed with SNP at the ages of 1) 8 years and 2 months, 2) 13 years and 2 months, 3) 16 years and 6 months, and patient 4) at the age of 6 years and 11 months - born small for gestational age (SGA). They underwent rhGH treatment.</p><p><strong>Results: </strong>The expected growth improvement was not observed in all boys. Patient 1 was diagnosed with aortic coarctation, and after each attempt to increase the rhGH dose, nocturnal vomiting occurred - epilepsy was diagnosed. Patient 2 had severe foot pain. Patient 3 had delayed puberty - hypogonadotropic hypogonadism was diagnosed. Patient 4 had dysmorphic features. Genetic tests revealed the following: 1) mixed gonadal dysgenesis - modifying treatment; 2) Fabry disease - enzyme treatment and rhGH improved growth; 3) Kallmann syndrome - discontinuing rhGH for testosterone supplementation; 4) KBG syndrome.</p><p><strong>Conclusions: </strong>1. The presence of dysmorphic features and symptoms atypical for growth hormone deficiencies could warrant genetic diagnostics before initiating treatment. 2. Lack of significant improvement in growth is an indication for reevaluation of patients who have not completed growth. 3. Genetic studies in this patient group often elucidate the causes of slow growth rate. 4. The case authors have developed a proposal for a multicentre program aimed at establishing indications for genetic diagnosis in children diagnosed with SNP and SGA treated with rhGH.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"30 2","pages":"51-60"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The partial clinical recovery phase (PCRP), or "honeymoon period", is a temporary and partial restoration of b-cell function in patients with type 1 diabetes mellitus (T1DM), in which the immune system attacks and destroys insulin-producing b-cells. The underlying causes of PCRP are not fully understood, but they are believed to involve a combination of genetic and environmental factors. Recent research has suggested a potential link between a specific allele of the prostaglandin receptor EP4 (PTGER4) and the modulation of remission in individuals with T1DM. This review aims to provide an overview of current scientific findings on the biological functions and role of the EP4 receptor in T1DM, with a particular focus on its involvement in the PCR phase. It provides a comprehensive understanding of the mechanisms underlying PCRP, which can lead to the development of more effective treatment strategies for preserving b-cell function and prolonging the PCRP. The identification of specific biomarkers associated with the PCRP and the EP4 receptor enables early identification of individuals at lower risk of long-term complications, facilitating targeted interventions and personalised treatment approaches.
{"title":"Role of EP4 factor in paediatric type 1 diabetes mellitus: a comprehensive review focusing on the honeymoon period.","authors":"Forough Taheri, Nekoo Panahi, Aida Vahidi, Mojgan Asadi, Mahsa M Amoli, Naieme Goharifar","doi":"10.5114/pedm.2024.146686","DOIUrl":"10.5114/pedm.2024.146686","url":null,"abstract":"<p><p>The partial clinical recovery phase (PCRP), or \"honeymoon period\", is a temporary and partial restoration of b-cell function in patients with type 1 diabetes mellitus (T1DM), in which the immune system attacks and destroys insulin-producing b-cells. The underlying causes of PCRP are not fully understood, but they are believed to involve a combination of genetic and environmental factors. Recent research has suggested a potential link between a specific allele of the prostaglandin receptor EP4 (PTGER4) and the modulation of remission in individuals with T1DM. This review aims to provide an overview of current scientific findings on the biological functions and role of the EP4 receptor in T1DM, with a particular focus on its involvement in the PCR phase. It provides a comprehensive understanding of the mechanisms underlying PCRP, which can lead to the development of more effective treatment strategies for preserving b-cell function and prolonging the PCRP. The identification of specific biomarkers associated with the PCRP and the EP4 receptor enables early identification of individuals at lower risk of long-term complications, facilitating targeted interventions and personalised treatment approaches.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"30 4","pages":"227-246"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.5114/pedm.2024.146687
Gerdi Tuli, Jessica Munarin, Francesco Quaglino, Giulia Carbonaro, Veronica Barat, Luisa de Sanctis, Franca Fagioli
Objectives: To describe medullary thyroid cancer (MTC) onset in a boy affected previously by Langerhans cell histiocytosis (LCH) and review the literature for other reports of this association.
Case presentation: A 6-year-old boy was treated for LCH diagnosis when he was 4 years old. After treatment, a rise in procalcitonin levels was observed (2.36-2.78 ng/ml) initially interpreted as inflammatory response. Further procalcitonin increase (4.61 ng/ml) with cervical lymphadenopathy and no infective focus was suspicious of thyroid involvement, confirmed by ultrasound, serum calcitonin, and cytological diagnosis. Total thyroidectomy with bilateral lymph node exeresis was performed. RET gene analysis revealed p.Met918Thr mutation. No association between the previous LCH and MTC had been identified to date.
Conclusions: MTC is a rare condition in childhood presenting with an aggressive behaviour. It becomes crucial to increase the awareness of its features and anticipate diagnosis. Therefore, persistent high levels of pro-calcitonin without infective/inflammatory focus should lead to suspicion of thyroid involvement.
{"title":"Medullary thyroid carcinoma in a 6-year-old boy with previous Langerhans cell histiocytosis presenting high level of pro-calcitonin.","authors":"Gerdi Tuli, Jessica Munarin, Francesco Quaglino, Giulia Carbonaro, Veronica Barat, Luisa de Sanctis, Franca Fagioli","doi":"10.5114/pedm.2024.146687","DOIUrl":"10.5114/pedm.2024.146687","url":null,"abstract":"<p><strong>Objectives: </strong>To describe medullary thyroid cancer (MTC) onset in a boy affected previously by Langerhans cell histiocytosis (LCH) and review the literature for other reports of this association.</p><p><strong>Case presentation: </strong>A 6-year-old boy was treated for LCH diagnosis when he was 4 years old. After treatment, a rise in procalcitonin levels was observed (2.36-2.78 ng/ml) initially interpreted as inflammatory response. Further procalcitonin increase (4.61 ng/ml) with cervical lymphadenopathy and no infective focus was suspicious of thyroid involvement, confirmed by ultrasound, serum calcitonin, and cytological diagnosis. Total thyroidectomy with bilateral lymph node exeresis was performed. RET gene analysis revealed p.Met918Thr mutation. No association between the previous LCH and MTC had been identified to date.</p><p><strong>Conclusions: </strong>MTC is a rare condition in childhood presenting with an aggressive behaviour. It becomes crucial to increase the awareness of its features and anticipate diagnosis. Therefore, persistent high levels of pro-calcitonin without infective/inflammatory focus should lead to suspicion of thyroid involvement.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"30 4","pages":"244-247"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nowadays, continuous glycaemic monitoring systems are used primarily for diabetic patients. The most popular continuous glycaemic monitoring (CGMs) measure the glucose concentration in the interstitial fluid every 1 or 5 minutes, providing the patient with 288 or 1,440 measurements in a day. CGM is also useful for observing sudden changes in glycaemia after the introduction of dietary interventions and those related to physical activity. Peri-prandial glycaemia is defined as the change in blood glucose levels depending on the carbohydrate-containing meal consumed. A state of peri-prandial hyperglycaemia begins when blood glucose levels rise above the level of 140 mg/dl (7.8 mmol/l) within 1-2 hours after food intake in healthy people without diabetes. The influence of the peri-prandial glycaemic response is briefly related to the amount and type of food consumed. Optimising the glycaemic profile is important for our health. The purpose of this article is to summarise the current knowledge of the effects of various meals on peri-prandial glycaemia in healthy individuals.
{"title":"Effects of different types of meals on postprandial glycaemia in healthy subjects.","authors":"Agnieszka Lejk, Karolina Myśliwiec, Przemysława Jarosz-Chobot","doi":"10.5114/pedm.2024.142587","DOIUrl":"10.5114/pedm.2024.142587","url":null,"abstract":"<p><p>Nowadays, continuous glycaemic monitoring systems are used primarily for diabetic patients. The most popular continuous glycaemic monitoring (CGMs) measure the glucose concentration in the interstitial fluid every 1 or 5 minutes, providing the patient with 288 or 1,440 measurements in a day. CGM is also useful for observing sudden changes in glycaemia after the introduction of dietary interventions and those related to physical activity. Peri-prandial glycaemia is defined as the change in blood glucose levels depending on the carbohydrate-containing meal consumed. A state of peri-prandial hyperglycaemia begins when blood glucose levels rise above the level of 140 mg/dl (7.8 mmol/l) within 1-2 hours after food intake in healthy people without diabetes. The influence of the peri-prandial glycaemic response is briefly related to the amount and type of food consumed. Optimising the glycaemic profile is important for our health. The purpose of this article is to summarise the current knowledge of the effects of various meals on peri-prandial glycaemia in healthy individuals.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"30 3","pages":"159-162"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.5114/pedm.2024.138666
Monika Pohorecka, Marcin Biernacki, Anna Jakubowska-Winecka, Kinga Leszczynska-Iwanicka, Dariusz Rokicki, Paulina Pokora, Barbara Perkowska, Magdalena Pajdowska, Marta Biernacka
Introduction: Tyrosinaemia type I is a rare hereditary metabolic disease caused by deficiency of the enzyme involved in the breakdown of tyrosine. Since the use of nitisinone in addition to diet in 1992, survival rates have increased significantly, but more and more socio-emotional problems have become apparent. The aim of the study was the assessment the relationship between variations in serum tyrosine and phenylalanine levels and measurements of socio-emotional functioning and determination of patients' IQs.
The aim of the study: was the assessment the relationship between variations in serum tyrosine and phenylalanine levels and measurements of socio-emotional functioning and determination of patients' IQs.
Material and methods: Twelve children were studied, from a single centre, born between 1994 and 2012, treated with nitisinone and a low-phenylalanine and -tyrosine diet. The psychological evaluation was conducted using the parent form of the Child Behaviour Checklist (CBCL)/4-18. Additionally, the patients' IQs were measured using the Stanford-Binet 5 (SB5) Intelligence Scale. Statistical analyses were performed using PAWS software suite version 26. We found that phenylalanine variability over time correlated with measures of emotional and behavioural functioning. This relationship holds true for externalising behaviour, associated with the experience of maladjustment and aggression. Total score intellectual and cognitive function was within the norm for all patients.
Conclusions: To maintain better quality of life for patients and their families in terms of emotional and behavioural functioning, it may be important to avoid spikes (significant fluctuations) in phenylalanine levels. Regular, detailed psychological evaluations are recommended to detect potential problems and implement interventions aimed at achieving the best possible individual development and realise the intellectual and behavioural potential, thereby improving the patient's and her family's quality of life.
导言酪氨酸血症 I 型是一种罕见的遗传性代谢疾病,由参与酪氨酸分解的酶缺乏引起。自 1992 年在饮食之外使用尼替西酮以来,存活率显著提高,但社会情感问题也越来越多。该研究的目的是评估血清中酪氨酸和苯丙氨酸水平的变化与社会情感功能测量和患者智商测定之间的关系:研究对象为来自一个中心的12名儿童,他们出生于1994年至2012年,接受了尼替西酮和低苯丙氨酸及酪氨酸饮食治疗。心理评估采用儿童行为检查表(CBCL)/4-18的家长表进行。此外,还使用斯坦福-比奈5(SB5)智力量表测量了患者的智商。统计分析使用 PAWS 软件套件 26 版进行。我们发现,苯丙氨酸随时间的变化与情绪和行为功能的测量结果相关。这种关系适用于与适应不良和攻击行为相关的外化行为。所有患者的智力和认知功能总分均符合标准:为了让患者及其家人在情绪和行为功能方面保持更好的生活质量,避免苯丙氨酸水平出现峰值(大幅波动)可能很重要。建议定期进行详细的心理评估,以发现潜在问题并采取干预措施,尽可能实现最佳的个体发展,发挥智力和行为潜能,从而提高患者及其家人的生活质量。
{"title":"Emotional and behavioural functioning in children with tyrosinaemia type 1.","authors":"Monika Pohorecka, Marcin Biernacki, Anna Jakubowska-Winecka, Kinga Leszczynska-Iwanicka, Dariusz Rokicki, Paulina Pokora, Barbara Perkowska, Magdalena Pajdowska, Marta Biernacka","doi":"10.5114/pedm.2024.138666","DOIUrl":"10.5114/pedm.2024.138666","url":null,"abstract":"<p><strong>Introduction: </strong>Tyrosinaemia type I is a rare hereditary metabolic disease caused by deficiency of the enzyme involved in the breakdown of tyrosine. Since the use of nitisinone in addition to diet in 1992, survival rates have increased significantly, but more and more socio-emotional problems have become apparent. The aim of the study was the assessment the relationship between variations in serum tyrosine and phenylalanine levels and measurements of socio-emotional functioning and determination of patients' IQs.</p><p><strong>The aim of the study: </strong>was the assessment the relationship between variations in serum tyrosine and phenylalanine levels and measurements of socio-emotional functioning and determination of patients' IQs.</p><p><strong>Material and methods: </strong>Twelve children were studied, from a single centre, born between 1994 and 2012, treated with nitisinone and a low-phenylalanine and -tyrosine diet. The psychological evaluation was conducted using the parent form of the Child Behaviour Checklist (CBCL)/4-18. Additionally, the patients' IQs were measured using the Stanford-Binet 5 (SB5) Intelligence Scale. Statistical analyses were performed using PAWS software suite version 26. We found that phenylalanine variability over time correlated with measures of emotional and behavioural functioning. This relationship holds true for externalising behaviour, associated with the experience of maladjustment and aggression. Total score intellectual and cognitive function was within the norm for all patients.</p><p><strong>Conclusions: </strong>To maintain better quality of life for patients and their families in terms of emotional and behavioural functioning, it may be important to avoid spikes (significant fluctuations) in phenylalanine levels. Regular, detailed psychological evaluations are recommended to detect potential problems and implement interventions aimed at achieving the best possible individual development and realise the intellectual and behavioural potential, thereby improving the patient's and her family's quality of life.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"30 1","pages":"8-13"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11037086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Type 1 diabetes mellitus (T1DM) is a health problem that can be difficult for young people to accept. The aim of this study is to determine the prevalence and characteristics of school failure in children with T1DM and to identify the associated factors.
Material and methods: This is a retrospective study conducted in the endocrinology department of the Farhat Hached Hospital in Sousse, regarding T1DM patients, by analysing their school and career paths according to their clinicobiological and social data. School failure was defined in our study by the presence of at least one year's repetition and/or exclusion from school.
Results: Our study included 70 patients. School failure was recorded in 71.4% of cases. School drop-out was observed in 47.1% of patients. The reasons for school drop-out were iterative hospitalizations in 31.4% of cases and glycaemic instability with hyper/hypoglycaemic fluctuations in 17.1%. Multivariate analysis showed that the risk factors significantly associated with school failure were, respectively, number of hospitalizations for ketosis ≥ 5 (p = 0.037) and higher mean HbA1c at the last consultations (p = 0.001). Use of functional insulin therapy (p = 0.031) and use of insulin analogue (p = 0.004) were significantly protective factors.
Conclusions: The risk of school failure in T1DM is real and should not be underestimated. Socioeconomic factors such as lack of financial resources, limited family support, and an unfavourable social environment can contribute to school avoidance.
{"title":"Prevalence and factors associated with school failure in children with type 1 diabetes.","authors":"Sawsen Nouira, Taieb Ach, Asma Ammar, Meriem Ach, Ghada Sabbagh, Olfa Ezzi, Asma Benabdelkrim","doi":"10.5114/pedm.2023.133124","DOIUrl":"10.5114/pedm.2023.133124","url":null,"abstract":"<p><strong>Introduction: </strong>Type 1 diabetes mellitus (T1DM) is a health problem that can be difficult for young people to accept. The aim of this study is to determine the prevalence and characteristics of school failure in children with T1DM and to identify the associated factors.</p><p><strong>Material and methods: </strong>This is a retrospective study conducted in the endocrinology department of the Farhat Hached Hospital in Sousse, regarding T1DM patients, by analysing their school and career paths according to their clinicobiological and social data. School failure was defined in our study by the presence of at least one year's repetition and/or exclusion from school.</p><p><strong>Results: </strong>Our study included 70 patients. School failure was recorded in 71.4% of cases. School drop-out was observed in 47.1% of patients. The reasons for school drop-out were iterative hospitalizations in 31.4% of cases and glycaemic instability with hyper/hypoglycaemic fluctuations in 17.1%. Multivariate analysis showed that the risk factors significantly associated with school failure were, respectively, number of hospitalizations for ketosis ≥ 5 (p = 0.037) and higher mean HbA1c at the last consultations (p = 0.001). Use of functional insulin therapy (p = 0.031) and use of insulin analogue (p = 0.004) were significantly protective factors.</p><p><strong>Conclusions: </strong>The risk of school failure in T1DM is real and should not be underestimated. Socioeconomic factors such as lack of financial resources, limited family support, and an unfavourable social environment can contribute to school avoidance.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"30 1","pages":"3-7"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11037087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141724695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.5114/pedm.2024.146685
Rebecca T Zimmer, Felix Aberer, Janis Schierbauer, Paul Zimmermann, Philipp Birnbaumer, Maria Fritsch, Elke Fröhlich-Reiterer, Peter Hofmann, Harald Sourij, Othmar Moser
Introduction: Real-time continuous glucose monitoring (rtCGM) has become an integral component of modern diabetes management. However, sensor performance data of adolescents, especially during exercise, are scarce. Therefore, this investigation aimed to determine the performance of a rtCGM-system before, during, and after exercise around a 4-week track and field training intervention in adolescents with type 1 diabetes (T1D).
Material and methods: Eight adolescents (2 females, 15.5 ±1.0 years, BMI: 21.0 ±2.3 kg/m2) with T1D and an HbA1c of 7.0 ±0.6% (53.0 ±6.6 mmol/mol) participated in a 4-week track and field intervention consisting of three 60-minute exercise sessions per week. Sensor glucose levels (Dexcom G6; Dexcom Inc., San Diego, CA) were obtained at rest and after 15, 30, 45, and 60 minutes during, as well as 5 minutes after exercise and compared to a reference capillary blood glucose value (Biosen S-Line, EKF Diagnostics, GER). rtCGM performance was assessed using the median absolute relative difference (MedARD) and interquartile range [IQR] as well as the Bland-Altman method.
Results: 443 points of comparison were available for analysis. The overall MedARD (IQR) was 19.1% (12.2-27.3). MedARDs for time in range (70-180 mg/dl), below range ( 180 mg/dl) were 22.0% (17.8-29.2), 28.4% (18.8-36.3), and 15.9% (9.4-20.7), respectively. The in-exercise MedARD was 19.4% (12.3-27.8), and pre- and post-exercise MedARDs were 21.6% (14.5-28.3) and 14.9% (9.0-21.6), respectively.
Conclusions: In structured track and field training involving adolescents with T1D, the accuracy of the Dexcom G6 system is limited. This supports the importance of considering glucose trend arrows and, when in doubt, blood measurements during exercise.
{"title":"Performance of real-time continuous glucose monitoring during track and field training in adolescents with type 1 diabetes.","authors":"Rebecca T Zimmer, Felix Aberer, Janis Schierbauer, Paul Zimmermann, Philipp Birnbaumer, Maria Fritsch, Elke Fröhlich-Reiterer, Peter Hofmann, Harald Sourij, Othmar Moser","doi":"10.5114/pedm.2024.146685","DOIUrl":"10.5114/pedm.2024.146685","url":null,"abstract":"<p><strong>Introduction: </strong>Real-time continuous glucose monitoring (rtCGM) has become an integral component of modern diabetes management. However, sensor performance data of adolescents, especially during exercise, are scarce. Therefore, this investigation aimed to determine the performance of a rtCGM-system before, during, and after exercise around a 4-week track and field training intervention in adolescents with type 1 diabetes (T1D).</p><p><strong>Material and methods: </strong>Eight adolescents (2 females, 15.5 ±1.0 years, BMI: 21.0 ±2.3 kg/m2) with T1D and an HbA1c of 7.0 ±0.6% (53.0 ±6.6 mmol/mol) participated in a 4-week track and field intervention consisting of three 60-minute exercise sessions per week. Sensor glucose levels (Dexcom G6; Dexcom Inc., San Diego, CA) were obtained at rest and after 15, 30, 45, and 60 minutes during, as well as 5 minutes after exercise and compared to a reference capillary blood glucose value (Biosen S-Line, EKF Diagnostics, GER). rtCGM performance was assessed using the median absolute relative difference (MedARD) and interquartile range [IQR] as well as the Bland-Altman method.</p><p><strong>Results: </strong>443 points of comparison were available for analysis. The overall MedARD (IQR) was 19.1% (12.2-27.3). MedARDs for time in range (70-180 mg/dl), below range ( 180 mg/dl) were 22.0% (17.8-29.2), 28.4% (18.8-36.3), and 15.9% (9.4-20.7), respectively. The in-exercise MedARD was 19.4% (12.3-27.8), and pre- and post-exercise MedARDs were 21.6% (14.5-28.3) and 14.9% (9.0-21.6), respectively.</p><p><strong>Conclusions: </strong>In structured track and field training involving adolescents with T1D, the accuracy of the Dexcom G6 system is limited. This supports the importance of considering glucose trend arrows and, when in doubt, blood measurements during exercise.</p>","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"30 4","pages":"211-220"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.5114/pedm.2024.144042
Małgorzata Wójcik, Agnieszka Zachurzok
{"title":"Obesity in children: inheritance and treatment - state of art 2024.","authors":"Małgorzata Wójcik, Agnieszka Zachurzok","doi":"10.5114/pedm.2024.144042","DOIUrl":"10.5114/pedm.2024.144042","url":null,"abstract":"","PeriodicalId":39165,"journal":{"name":"Pediatric Endocrinology, Diabetes and Metabolism","volume":"30 3","pages":"112-115"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}